Allspring Global Investments Holdings LLC reduced its position in shares of Abrdn Life Sciences Investors (NYSE:HQL - Free Report) by 19.1% during the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 280,302 shares of the company's stock after selling 66,319 shares during the quarter. Allspring Global Investments Holdings LLC owned about 1.02% of Abrdn Life Sciences Investors worth $4,227,000 as of its most recent filing with the Securities & Exchange Commission.
Several other institutional investors also recently bought and sold shares of HQL. Cetera Advisors LLC purchased a new position in shares of Abrdn Life Sciences Investors in the 1st quarter valued at $1,929,000. Oppenheimer & Co. Inc. lifted its position in Abrdn Life Sciences Investors by 4.6% during the 1st quarter. Oppenheimer & Co. Inc. now owns 18,414 shares of the company's stock worth $251,000 after acquiring an additional 814 shares during the period. Sanctuary Advisors LLC acquired a new stake in Abrdn Life Sciences Investors during the 2nd quarter worth about $154,000. B. Riley Wealth Advisors Inc. acquired a new stake in Abrdn Life Sciences Investors during the 1st quarter worth about $143,000. Finally, Wedbush Securities Inc. lifted its position in Abrdn Life Sciences Investors by 8.2% during the 2nd quarter. Wedbush Securities Inc. now owns 16,673 shares of the company's stock worth $236,000 after acquiring an additional 1,261 shares during the period. 32.21% of the stock is currently owned by hedge funds and other institutional investors.
Abrdn Life Sciences Investors Stock Performance
HQL traded down $0.07 on Tuesday, reaching $14.89. 45,447 shares of the stock were exchanged, compared to its average volume of 93,777. The company's 50-day moving average price is $15.11 and its 200 day moving average price is $14.49. Abrdn Life Sciences Investors has a fifty-two week low of $11.43 and a fifty-two week high of $15.90.
Abrdn Life Sciences Investors Increases Dividend
The business also recently declared a quarterly dividend, which was paid on Monday, September 30th. Stockholders of record on Friday, August 23rd were given a $0.49 dividend. The ex-dividend date of this dividend was Friday, August 23rd. This is a positive change from Abrdn Life Sciences Investors's previous quarterly dividend of $0.48. This represents a $1.96 dividend on an annualized basis and a dividend yield of 13.16%.
Abrdn Life Sciences Investors Profile
(
Free Report)
Abrdn Life Sciences Investors is a closed-ended equity mutual fund launched and managed by abrdn Inc The fund invests in public equity markets across the globe. It seeks to invest in stocks of companies operating in the life sciences sector, including the biotechnology, pharmaceutical, diagnostics, managed healthcare, medical equipment, hospitals, healthcare information technology and services, devices and supplies industries, and in agriculture and environmental management industries.
See Also
Before you consider Abrdn Life Sciences Investors, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Abrdn Life Sciences Investors wasn't on the list.
While Abrdn Life Sciences Investors currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
